Objectives Randomized controlled trials have shown that cyclophosphamide (CYC) was an
option in systemic sclerosis-associated interstitial lung disease (SSc-ILD). The observed …

Objective To investigate the long-term disease course of patients with recently deteriorated
systemic sclerosis (SSC)-interstitial lung disease (ILD) undergoing continuous …

Objective. To report the efficacy and tolerability of mycophenolate mofetil (MMF) and
azathioprine (AZA) in the management of systemic sclerosis-associated interstitial lung …

Objective. To compare safety and efficacy outcomes between the cyclophosphamide (CYC)
arms of Scleroderma Lung Study (SLS) I and II. Methods. Participants enrolled in the CYC …

Objective Cyclophosphamide is considered the treatment of choice for interstitial lung
disease (ILD) secondary to systemic sclerosis (SSc), albeit having a minimal effect. Although …

Objective To evaluate the effects and safety of 6-month intravenous cyclophosphamide
(CYC) followed by 18-month oral azathioprine (AZA) therapy in patients with systemic …

Objective This study systematically compares the efficacy and adverse events of
mycophenolate mofetil (MMF) and cyclophosphamide (CYC) in patients with systemic …

Interstitial lung disease (ILD) is the leading cause of mortality in patients with systemic
sclerosis (SSc), which is also known as scleroderma. Two randomized clinical trials in …

Objective We sought to determine the effectiveness of mycophenolate mofetil (MMF) in
scleroderma-associated interstitial lung disease (SSc-ILD). Methods We retrospectively …

Objective: Interstitial lung disease (ILD) frequently complicates systemic sclerosis (SSc).
Cyclophosphamide (CYC) is a promising immunosuppressive therapy for SSc-related ILD …